Hyponatremia, whether due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) or disorders of water retention such as congestive heart failure and cirrhosis, is a very common problem encountered in the care of medical patients. To date, available treatment modalities for disorders of excess arginine vasopressin (AVP) secretion or action have been limited and suboptimal. The recent discovery and development of nonpeptide AVP V(2) receptor antagonists represents a promising new treatment option to directly antagonize the effects of elevated plasma AVP concentrations at the level of the renal collecting ducts. By decreasing the water permeability of renal collecting tubules, excretion of retained water is promoted, thereby normalizing or improving hypo-osmolar hyponatremia. In this review, SIADH and other water retaining disorders are briefly discussed, after which the published preclinical and clinical studies of several nonpeptide AVP V(2) receptor antagonists are summarized. The likely therapeutic indications and potential complications of these compounds are also described.

This article has been cited by other articles:

				J. Perucca, D. G. Bichet, P. Bardoux, N. Bouby, and L. Bankir Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1721 - 1731. [Abstract] [Full Text] [PDF]

				P. M. O'Connor and A. W. Cowley Jr. Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway Am J Physiol Renal Physiol, August 1, 2007; 293(2): F526 - F532. [Abstract] [Full Text] [PDF]

				A. S. Multz Vasopressin Dysregulation and Hyponatremia in Hospitalized Patients J Intensive Care Med, July 1, 2007; 22(4): 216 - 223. [Abstract] [PDF]

				K. A. Walter Conivaptan: New treatment for hyponatremia Am. J. Health Syst. Pharm., July 1, 2007; 64(13): 1385 - 1395. [Abstract] [Full Text] [PDF]

				L. Bankir, J. Perucca, and M. H. Weinberger Ethnic Differences in Urine Concentration: Possible Relationship to Blood Pressure Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 304 - 312. [Abstract] [Full Text] [PDF]

				G. Decaux, F. Vandergheynst, Y. Bouko, J. Parma, G. Vassart, and C. Vilain Nephrogenic Syndrome of Inappropriate Antidiuresis in Adults: High Phenotypic Variability in Men and Women from a Large Pedigree J. Am. Soc. Nephrol., February 1, 2007; 18(2): 606 - 612. [Abstract] [Full Text] [PDF]

				A. Soupart, P. Gross, J.-J. Legros, S. Alfoldi, D. Annane, H. M. Heshmati, and G. Decaux Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1154 - 1160. [Abstract] [Full Text] [PDF]

				L. E. Wagoner, R. C. Starling, and C. M. O'Connor Cardiac Function and Heart Failure J. Am. Coll. Cardiol., June 6, 2006; 47(11_Suppl_D): D18 - D22. [Full Text] [PDF]

				J. K. Ghali, M. J. Koren, J. R. Taylor, E. Brooks-Asplund, K. Fan, W. A. Long, N. Smith, and for the Conivaptan Study Group Efficacy and Safety of Oral Conivaptan: A V1A/V2 Vasopressin Receptor Antagonist, Assessed in a Randomized, Placebo-Controlled Trial in Patients with Euvolemic or Hypervolemic Hyponatremia J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2145 - 2152. [Abstract] [Full Text] [PDF]

				J. P. Chute, E. Taylor, J. Williams, F. Kaye, D. Venzon, and B. E. Johnson A Metabolic Study of Patients with Lung Cancer and Hyponatremia of Malignancy Clin. Cancer Res., February 1, 2006; 12(3): 888 - 896. [Abstract] [Full Text] [PDF]

				S. R. Goldsmith and M. Gheorghiade Vasopressin Antagonism in Heart Failure J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1785 - 1791. [Abstract] [Full Text] [PDF]

				T. Miyazaki, Y. Yamamura, T. Onogawa, S. Nakamura, S. Kinoshita, S. Nakayama, H. Fujiki, and T. Mori Therapeutic Effects of Tolvaptan, a Potent, Selective Nonpeptide Vasopressin V2 Receptor Antagonist, in Rats with Acute and Chronic Severe Hyponatremia Endocrinology, July 1, 2005; 146(7): 3037 - 3043. [Abstract] [Full Text] [PDF]

				A. Hassan, Y. Tian, W. Zheng, H. Ji, K. Sandberg, and J. G. Verbalis Small interfering RNA-mediated functional silencing of vasopressin V2 receptors in the mouse kidney Physiol Genomics, May 11, 2005; 21(3): 382 - 388. [Abstract] [Full Text] [PDF]

				B. J. Feldman, S. M. Rosenthal, G. A. Vargas, R. G. Fenwick, E. A. Huang, M. Matsuda-Abedini, R. H. Lustig, R. S. Mathias, A. A. Portale, W. L. Miller, et al. Nephrogenic Syndrome of Inappropriate Antidiuresis N. Engl. J. Med., May 5, 2005; 352(18): 1884 - 1890. [Abstract] [Full Text] [PDF]

				B. W. M. van Balkom, J. D. Hoffert, C.-L. Chou, and M. A. Knepper Proteomic analysis of long-term vasopressin action in the inner medullary collecting duct of the Brattleboro rat Am J Physiol Renal Physiol, February 1, 2004; 286(2): F216 - F224. [Abstract] [Full Text] [PDF]